Keytruda Misses on Melanoma OS | Oncologists & Sexual Harassment | Sexual Dysfunction Side EffectsJune 15, 2021 | Oncology Dermatology Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma Presented at the virtual American Society of Clinical Oncology (ASCO) annual meeting, the findings from the S1404 clinical trial demonstrated that, although the PD-1 inhibitor pembrolizumab (Keytruda) came up short in both the intent-to-treat (ITT) population and PD-L1-positive subgroup, relapse-free survival (RFS) was significantly improved compared with those who received either ipilimumab (Yervoy) or high-dose interferon. Read full article Oncology, Medical Sexual Harassment of Oncologists There have been few studies that have used validated measures to investigate the sexual harassment of physicians, never mind the sexual harassment of oncologists. According to the authors, this report is the first of its kind to examine the prevalence and types of sexual harassment experienced by oncologists, measuring their work experiences in three forms: sexual attention, sexual coercion, and gender harassment. Read full article Endocrinology, Diabetes, Metabolism 9 Drugs That Can Affect Your Sex Drive Both men and women can be affected by medications that cause unwanted side effects, one of which can be sexual dysfunction. It’s important to talk to your patients about how to manage their primary conditions while working with them to alleviate the problems associated with these common medications that affect sex drive. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS